| Project/Area Number |
23K14598
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50010:Tumor biology-related
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
YAN Chen 長崎大学, 原爆後障害医療研究所, 講師 (70968396)
|
|---|
| Project Period (FY) |
2023-04-01 – 2024-03-31
|
| Project Status |
Discontinued (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2024: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2023: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | Cancer stem cells / Mitophagy / Cancer |
|---|
| Outline of Research at the Start |
Cancer stem cells (CSCs) are known to associate with therapeutic resistance and cancer relapse. We will investigate the role and mechanism of mitophagy in maintaining the biological characteristics of CSCs. Our study will provide new insight into mechanism on the biological characteristics of CSCs.
|
| Outline of Annual Research Achievements |
To investigate the potential role of mitophagy in maintaining the biological characteristics of cancer stem cells, human colorectal cancer cells (HCT116) were used in experiments. We found that Mdivi-1, a pharmacological mitophagy inhibitor, slightly decreased the clonogenic formation ability of HCT116 cells. Interestingly, doxorubicin treatment of HCT116 cells for 7 days upregulated several mitophagy-related genes and increased mitophagy activity, but inversely decreased the expression of cancer stem cell markers (Sox2 and c-myc). Further studies are warranted to elucidate the precise role and relevant mechanism of mitophagy in cancer stem cells.
|
